Meeting
2014 ASCO Annual Meeting
A phase III trial of postoperative chemotherapy or no further treatment for patients with node-negative stage I-II intermediate- or high-risk endometrial cancer. ENGOT-EN2-DGCG/EORTC 55102.
Authors
Mansoor Raza Mirza
Danish Gynecologic Cancer Group, Copenhagen, Denmark
Mansoor Raza Mirza , Caroline Lundgren , Frederic Kridelka , Annamaria Ferrero , Frederic Amant
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Uterine Cancer
Clinical Trial Registration Number
NCT01244789
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr TPS5628)
DOI
10.1200/jco.2014.32.15_suppl.tps5628
Abstract #
TPS5628
Poster Bd #
401B
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
ENGOT-en9/LEAP-001: A phase III study of first-line pembrolizumab plus lenvatinib versus chemotherapy in advanced or recurrent endometrial cancer.
First Author: Christian Marth
Poster
2019 ASCO Annual Meeting
AtTEnd/ENGOT-en7: A multicenter phase III double-blind randomized controlled trial of atezolizumab in combination with paclitaxel and carboplatin in women with advanced/recurrent endometrial cancer.
First Author: Nicoletta Colombo
Poster
2011 ASCO Annual Meeting
Paradigm shift in the management of high-intermediate risk stage I endometrial cancer.
First Author: J. O. Schorge
Poster
2023 ASCO Annual Meeting
Randomized phase III trial in MMR deficient (MMRd) endometrial cancer (EC) patients comparing chemotherapy (CT) alone versus dostarlimab in first line advanced/metastatic setting: DOMENICA study (GINECO-EN105b/ENGOT-en13 study).
First Author: Florence Joly